ArticleAmerican journal of translational research2025
Elevated TXNIP and reduced PINK1 in gestational diabetes mellitus: association with dyslipidemia and pregnancy complications.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the association between thioredoxin-interacting protein (TXNIP), PTEN-induced putative kinase 1 (PINK1) and lipid metabolism in gestational diabetes mellitus (GDM), and to assess their clinical significance.
methodsThis case-control study included 220 pregnant women (110 with GDM and 110 healthy controls) recruited from 2022 to 2024. Clinical assessments included glucose, lipids, and thyroid function profiles. TXNIP and PINK1 mRNA expression were measured using RT-qPCR. Pregnancy outcomes were documented using standardized clinical protocols.
resultsCompared to controls, GDM patients had significantly higher fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPBG), glycated hemoglobin (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR), along with reduced fasting insulin (FINS). Thyroid function tests showed elevated triiodothyronine (T3), and thyroxine (T4) levels in the GDM group. Lipid profiles revealed increased triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C). TXNIP expression was significantly elevated, while PINK1 expression was decreased in GDM patients. Correlation analysis indicated strong associations between TXNIP and PINK1 levels with lipid values. GDM was also associated with adverse pregnancy outcomes, including higher rates of cesarean delivery, preterm birth, macrosomia, neonatal hypoglycemia, and lower Apgar scores.
conclusionsDyslipidemia in GDM-characterized by elevated TC, TG, and LDL-C and decreased HDL-C-may be associated with upregulation of TXNIP and downregulation of PINK1. These molecular alterations could contribute to metabolic disturbances and poor pregnancy outcomes. Monitoring lipid profiles alongside TXNIP and PINK1 expression may aid in the clinical management of GDM and its complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.